Registry for Stage 2 Type 1 Diabetes
← catalyst calendarNCT06481904 · readout in 3,802 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
200estimated
Sites
37
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-09-27 | actual | When the study began enrolling |
| Primary completion | 2037-01-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2037-01-15 | estimated | The whole study's end, after follow-up |
| First posted | 2024-07-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Type 1 Diabetes
Intervention
- Drug: TZIELD (teplizumab-mzwv)
Primary outcomes
what the primary-completion date above is the date OFNumber of adverse events of special interests (AESI)
measured Throughout the study, approximately 10 years
Number of serious adverse events (SAE)
measured Throughout the study, approximately 10 years
Number of adverse events (AE) in mothers, fetuses, and infants exposed to TZIELD during pregnancy
measured From start of pregnancy to 12 months post-partum
Number of maternal pregnancy-related events
measured From start of pregnancy to 12 months post-partum
Developmental outcomes of the infant
measured From birth of infant to 12 months
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed